NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.
about
Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesCutaneous adverse reactions specific to epidermal growth factor receptor inhibitorsOverview and management of dermatologic events associated with targeted therapies for medullary thyroid cancerAZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerPatient considerations in metastatic colorectal cancer - role of panitumumab.Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial.The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors.Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.Looking to the future: incorporating genomic information into disparities research to reduce measurement error and selection bias.Targeted agent use in cancer patients at the end of lifeA comparison of epithelial-to-mesenchymal transition and re-epithelializationManagement of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case reviewDaily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel.Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology.Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid TumorsSemiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials.Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.Dermatologic Reactions to Targeted Therapy: A Focus on Epidermal Growth Factor Receptor Inhibitors and Nursing Care.Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.Successful treatment of epidermal growth factor receptor inhibitor-induced alopecia with doxycycline.Minocycline Improves the Efficacy of EGFR Inhibitor Therapy: A Hypothesis.Safety profiles of current antiangiogenic therapies for metastatic colorectal cancerCetuximab-induced esophageal ulcer: the first report in literatureA survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies.Label-free real-time ultrasensitive monitoring of non-small cell lung cancer cell interaction with drugs
P2860
Q26751274-5501304A-CD4A-471F-8809-8AD14D122D86Q26781472-19A7AC97-7950-4407-A79B-31D90ED58357Q27005701-9B5CC562-19A4-4559-8A21-7E2C137FABB9Q27853013-0D6804E1-4E55-4F10-8B71-A458C8F62521Q33563293-E8A1B5A0-9D9C-4C5D-AC22-CD712A014335Q33733218-BA1EFF33-644C-47C0-BAC8-1A97DB2B532DQ33865354-15436A90-003B-4045-BFE2-D0B047562F69Q33885559-ED5B83A0-1EC2-4594-9631-A891B72543F0Q35083960-E570946C-8CF8-4A2A-98B8-2525C440230CQ35913241-F0AF8BA1-C31E-411F-B1CB-0108FA8341A2Q36163437-0AA548E7-7AAC-4F26-B157-A06DBCF07FF4Q36675356-EC3E3C05-FE0E-4F67-AFE7-725EE906EE4BQ36678367-FB5F9750-FE0A-46CC-B5AC-542A85B64A0DQ37369678-6F4E5F8A-E521-45A6-B9A9-4270F57743BBQ37390753-3EC16F01-E531-483C-8C7F-1A9638C11CCEQ37442683-6BC1B7CE-56F6-45C7-BF6E-5B7C5FA3CFF8Q37496672-A2D73871-43DC-4493-9C54-0DFEFDED4332Q37987802-9210F2D8-41D4-4E0B-82E0-A07BFC2452A4Q38025317-A111FE60-A6A2-459B-8A70-C5403E570887Q38059784-303EA061-2BAB-481E-B62A-3FF5D7ABEC7CQ38074290-F4149703-71B9-43FA-8058-10FF16A35A04Q38262804-82607302-FDCD-467D-8B32-D6BFFEEC8EA0Q38355156-A7755E22-651C-4C2E-A852-235C12F424B4Q39131525-D54A2CE3-C023-4030-9A10-8957B9099BC6Q39278689-85E01770-A6E6-4E18-B27C-CDF4B4CB3AF3Q39554373-489729FA-5513-4BF6-9A67-2741C2621C7BQ40456709-5C297F97-0393-4211-A0C6-B0E331B4EEE9Q41947800-C42FD2DF-12D8-4BC5-8273-E04C209A70E8Q42429922-A0F63D04-45E8-4DC5-8D33-926657F65BF7Q50108934-594405B4-6471-46AA-BF2C-40760F51EB8FQ58796615-67646F93-C616-457E-962B-8B44C2C9E6BF
P2860
NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
NCCN Task Force Report: Manage ...... ition in patients with cancer.
@en
NCCN Task Force Report: Manage ...... ition in patients with cancer.
@nl
type
label
NCCN Task Force Report: Manage ...... ition in patients with cancer.
@en
NCCN Task Force Report: Manage ...... ition in patients with cancer.
@nl
prefLabel
NCCN Task Force Report: Manage ...... ition in patients with cancer.
@en
NCCN Task Force Report: Manage ...... ition in patients with cancer.
@nl
P2093
P356
P1476
NCCN Task Force Report: Manage ...... bition in patients with cancer
@en
P2093
Barbara Burtness
Clifford S Perlis
Jennifer Paul
Joan S McClure
Leonard Saltz
Milan Anadkat
Miranda Hughes
Patricia L Myskowski
Sharon Spencer
Surendra Basti
P304
S5-21; quiz S22-4
P356
10.6004/JNCCN.2009.0074
P478
P577
2009-05-01T00:00:00Z